Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 9, 2009 - Issue 8
Submit an article Journal homepage
237
Views
21
CrossRef citations to date
0
Altmetric
Drug Evaluations

The role of natalizumab in hematopoietic stem cell mobilization

Frank Neumann Heinrich-Heine-University, Department of Hematology, Oncology and Clinical Immunology, Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany +49 211 8117720; +49 211 8118853; [email protected]
,
Fabian Zohren Heinrich-Heine-University, Department of Hematology, Oncology and Clinical Immunology, Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany +49 211 8117720; +49 211 8118853; [email protected]
&
Rainer Haas Heinrich-Heine-University, Department of Hematology, Oncology and Clinical Immunology, Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany +49 211 8117720; +49 211 8118853; [email protected]
Pages 1099-1106 | Published online: 01 Jul 2009

Bibliography

  • Ransohoff RM. Natalizumab for multiple sclerosis. N Engl J Med 2007;356:2622-9
  • Rice GP, Hartung HP, Calabresi PA. Anti-α4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005;64:1336-42
  • Ghosh S. Therapeutic value of alpha-4 integrin blockade in inflammatory bowel disease:the role of natalizumab. Expert Opin Biol Ther 2003;3:995-1000
  • Verfaillie CM, Hurley R, Bhatia R, et al. Role of bone marrow matrix in normal and abnormal hematopoiesis. Crit Rev Oncol Hematol 1994;16:201-24
  • Prosper F, Stroncek D, Mccarthy JB, et al. Mobilization and homing of peripheral blood progenitors is related to reversible downregulation of α4β1 integrin expression and function. J Clin Invest 1998;101:2456-67
  • Whetton AD, Graham GJ. Homing and mobilization in the stem cell niche. Trends Cell Biol 1999;9:233-8
  • Miyake K, Weissman IL, Greenberger JS, et al. Evidence for a role of the integrin VLA-4 in lympho-hemopoiesis. J Exp Med 1991;173:599-607
  • Yanai N, Sekine C, Yagita H, et al. Roles for integrin very late activation antigen-4 in stroma-dependent erythropoiesis. Blood 1994;83:2844-50
  • Hamamura K, Matsuda H, Takeuchi Y, et al. A critical role of VLA-4 in erythropoiesis in vivo. Blood 1996;87:2513-7
  • Soligo D, Schiro R, Luksch R, et al. Expression of integrins in human bone marrow. Br J Haematol 1990;76:323-32
  • Verfaillie CM, Mccarthy JB, Mcglave PB. Differentiation of primitive human multipotent hematopoietic progenitors into single lineage clonogenic progenitors is accompanied by alteration in their interaction with fibronectin. J Exp Med 1991;174:693-703
  • Simmons PJ, Masinovsky B, Longenecker BM, et al. Vascular cell adhesion molecule-1 expressed by bone marrow stromal cells mediates the binding of hematopoietic progenitor cells. Blood 1992;80:388-95
  • Teixido J, Hemler ME, Greenberger JS, et al. Role of β1 and β2 integrins in the adhesion of human CD34hi stem cells to bone marrow stroma. J Clin Invest 1992;90:358-67
  • Liesveld JL, Winslow JM, Frediani KE, et al. Expression of integrins and examination of their adhesive function in normal and leukemic hematopoietic cells. Blood 1993;81:112-21
  • Kinashi T, Springer TA. Adhesion molecules in hematopoietic cells. Blood Cells 1994;20:25-44
  • Möhle R, Murea S, Kirsch M, et al. Differential expression of L-selectin, VLA-4, and LFA-1 on CD34+ progenitor cells from bone marrow and peripheral blood during G-CSF-enhanced recovery. Exp Hematol 1995;23:1535-42
  • Leavesley DI, Oliver JM, Swart BW, et al. Signals from platelet/endothelial cell adhesion molecule enhance the adhesive activity of the very late antigen-4 integrin of human CD34+ hemopoietic progenitor cells. J Immunol 1994;153:4673-83
  • Yamaguchi M, Ikebuchi K, Hirayama F, et al. Different adhesive characteristics and VLA-4 expression of CD34+ progenitors in G0/G1 versus S+G2/M phases of the cell cycle. Blood 1998;92:842-8
  • Bellucci R, De Propris MS, Buccisano F et al. Modulation of VLA-4 and L-selectin expression on normal CD34+ cells during mobilization with G-CSF. Bone Marrow Transplant 1999;23:1-8
  • Lichterfeld M, Martin S, Burkly L, et al. Mobilization of CD34+ haematopoietic stem cells is associated with a functional inactivation of the integrin very late antigen 4. Br J Haematol 2000;110:71-81
  • Papayannopoulou T, Nakamoto B. Peripheralization of hemopoietic progenitors in primates treated with anti-VLA4 integrin. Proc Natl Acad Sci USA 1993;90:9374-8
  • Craddock CF, Nakamoto B, Andrews RG, et al. Antibodies to VLA4 integrin mobilize long-term repopulating cells and augment cytokine-induced mobilization in primates and mice. Blood 1997;90:4779-88
  • Vermeulen M, Lepesteur F, Gagnerault MC, et al. Role of adhesion molecules in the homing and mobilization of murine hematopoietic stem and progenitor cells. Blood 1998;92:894-900
  • Papayannopoulou T, Priestley GV, Nakamoto B. Anti-VLA4/VCAM-1-induced mobilization requires cooperative signaling through the kit/mkit ligand pathway. Blood 1998;91:2231-9
  • Papayannopoulou T, Craddock C, Nakamoto B, et al. The VLA4/VCAM-1 adhesion pathway defines contrasting mechanisms of lodgement of transplanted murine hemopoietic progenitors between bone marrow and spleen. Proc Natl Acad Sci USA 1995;92:9647-51
  • Faull RJ, Ginsberg MH. Dynamic regulation of integrins. Stem Cells 1995;13:38-46
  • Shattil SJ, Kashiwagi H, Pampori N. Integrin signaling: the platelet paradigm. Blood 1998;91:2645-57
  • Huttenlocher A, Ginsberg MH, Horwitz AF. Modulation of cell migration by integrin-mediated cytoskeletal linkages and ligand-binding affinity. J Cell Biol 1996;134:1551-62
  • Martin-Bermudo MD, Dunin-Borkowski OM, Brown NH. Modulation of integrin activity is vital for morphogenesis. J Cell Biol 1998;141:1073-81
  • Zohren F, Toutzaris D, Klaerner V, et al. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 2008;111:3893-5
  • Bonig H, Wundes A, Chang KH, et al. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 2008;111:3439-41
  • Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008;14:1045-56
  • Bruns I, Steidl U, Kronenwett R, et al. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion 2006;46:180-5
  • Kroschinsky F, Hölig K, Platzbecker U, et al. Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma. Transfusion 2006;46:1417-23
  • Calandra G, Mccarty J, Mcguirk J, et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008;41:331-8
  • Cashen A, Lopez S, Gao F, et al. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant 2008;14:1253-61
  • Devine SM, Flomenberg N, Vesole DH, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004;22:1095-102
  • Flomenberg N, Devine SM, Dipersio JF, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005;106:1867-74
  • Podolsky DK. Selective adhesion-molecule therapy and inflammatory bowel disease – a tale of Janus? N Engl J Med 2005;353:1965-8
  • Hauser SL, Weiner HL. Natalizumab: immune effects and implications for therapy. Ann Neurol 2006;59:731-2
  • Ropper AH. Selective treatment of multiple sclerosis. N Engl J Med 2006;354:965-7
  • Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
  • Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-23
  • Hesterberg PE, Winsor-Hines D, Briskin MJ, et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology 1996;111:1373-80
  • Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn's disease. Gastroenterology 2001;121:268-74
  • Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32
  • Elices MJ. Natalizumab. Elan/Biogen. Curr Opin Investig Drugs 2003;4:1354-62
  • Ropper AH. Selective treatment of multiple sclerosis. N Engl J Med 2006;354:965-7
  • Available from: http://investor.biogenidec.com/phoenix.zhtml?c=148682 & p=irol-TPME
  • Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-8
  • Kleinschmidt-Demasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369-74
  • Krumbholz M, Meinl I, Kümpfel T, et al. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 2008;71:1350-4
  • Khatri BO, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 2009;72:402-9
  • Stuve O, Marra CM, Cravens PD, et al. Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch Neurol 2007;64:169-76
  • Phillips JT, O'Connor PW, Havrdova E, et al. Infusion-related hypersensitivity reactions during natalizumab treatment. Neurology 2006;67:1717-8
  • Ghosh S, Goldin E, Gordon FH. Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32
  • Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23
  • Christ O, Kronenwett R, Haas R, et al. Exp Hematol 2001;29:380-90
  • Becker PS, Appelbaum FR, Chien S. Oral small molecule inhibitor of VLA-4 overcomes adhesion mediated chemotherapy resistance of acute myeloid leukemia (AML) blasts in vitro, without impairment of normal blood cell recovery when combined with chemotherapy in vivo. Oral Presentation 858, San Francisco: Annual Meeting of the American Society of Hematology, 2008 [abstract 858]. Blood (ASH Annual Meeting Abstracts) 2008;112
  • Matsunaga T, Fukai F, Miura S, et al. Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia. Leukemia 2008;22:353-60
  • Becker PS, Kopecky KJ, Wilks AN, et al. Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia. Blood 2009;113:866-74
  • Noborio-Hatano K, Kikuchi J, Takatoku M, et al. Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene 2009;28:231-42
  • Rose DM. The role of the α4 integrin–paxillin interaction in regulating leukocyte trafficking. Exp Mol Med 2006;38:191-5
  • Bonig H, Watts KL, Chang KH, et al. Concurrent blockade of α4-integrin and CXCR4 in hematopoietic stem/progenitor cell mobilization. Stem Cells 2009;27:836-7

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.